Works matching IS 15430790 AND DT 2025 AND VI 23
Results: 29
Golcadomide ± Rituximab Demonstrates Durable Efcacy and Is Well Tolerated in Patients With R/R FL: Updated Results From the Phase 1/2 CC-99282-NHL-001 Study.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 13
- Publication type:
- Article
Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients With R/R FL: 2-Year Follow-up From Arm 2 of the EPCORE NHL-2 Trial.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 12
- Publication type:
- Article
Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 10
- Publication type:
- Article
Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients With Previously Untreated DLBCL With High-Risk Features: Long-Term Results From the EPCORE NHL-2 Trial.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 8
- Publication type:
- Article
Three-Year Update From the EPCORE NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in R/R LBCL.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 7
- Publication type:
- Article
Longer Follow-up of Golcadomide, a Cereblon E3 Ligase Modulator (CELMoD™) Agent, ± Rituximab in Patients With R/R DLBCL.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 5
- Publication type:
- Article
Tafasitamab + Lenalidomide and Rituximab for R/R FL: Results From a Phase 3 Study (inMIND).
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 3
- Publication type:
- Article
Golcadomide + R-CHOP Has High MRD Negativity Across High-Risk, Untreated a-BCL.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 2
- Publication type:
- Article
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2- Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 13
- Publication type:
- Article
AFT-38 PATINA: A Randomized, Open-Label, Phase 3 Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for HR+/HER2+ Metastatic Breast Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 12
- Publication type:
- Article
Quality-Adjusted Time Without Symptoms of Disease Progression or Toxicity of Treatment (Q-TWiST) Analysis of Sacituzumab Govitecan vs Chemotherapy in Previously Treated Patients with HR+/HER2-Metastatic Breast Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 10
- Publication type:
- Article
PRESERVE 2: A Randomized, Phase 3, Double-Blind Trial of Trilaciclib or Placebo in Patients Receiving First-Line Gemcitabine/Carboplatin for Locally Advanced or Metastatic Triple-Negative Breast Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 9
- Publication type:
- Article
Efficacy and Safety of Trastuzumab Deruxtecan vs Physician's Choice of Chemotherapy by Pace of Disease Progression on Prior Endocrine-Based Therapy: Additional Analysis From DESTINY-Breast06.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 6
- Publication type:
- Article
Primary Results of the Randomized Phase 4 Trial Comparing First-Line Endocrine Therapy + Palbociclib vs Standard Mono-chemotherapy in Women With High-Risk HER2-/HR+ Metastatic Breast Cancer and Indication for Chemotherapy: PADMA Study.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 5
- Publication type:
- Article
Preliminary Efficacy and Safety of the BTK Degrader BGB-16673 in Patients With R/R CLL/Small Lymphocytic Lymphoma: Results From the Phase 1 CaDAnCe-101 Study.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 12
- Publication type:
- Article
Efficacy and Safety of the BTK Degrader NX-5948 in Patients With R/R CLL: Updated Results From an Ongoing Phase 1a/b Study.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 11
- Publication type:
- Article
Epcoritamab Monotherapy in Patients With R/R CLL: Results From CLL Expansion and Optimization Cohorts of EPCORE CLL-1.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 9
- Publication type:
- Article
BRUIN CLL-321: Randomized Phase 3 Trial of Pirtobrutinib vs Idelalisib + Rituximab or Bendamustine + Rituximab in BTK Inhibitor--Pretreated CLL/Small Lymphocytic Lymphoma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 7
- Publication type:
- Article
Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates With Good Tolerability: Data From an Ongoing Phase 1/1b Study BGB-11417-101.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 5
- Publication type:
- Article
Combined Pirtobrutinib, Venetoclax, and Obinutuzumab as First-Line Treatment of Patients With CLL.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 4
- Publication type:
- Article
Fixed-Duration Acalabrutinib + Venetoclax With or Without Obinutuzumab vs Chemoimmunotherapy for First-Line Treatment of CLL: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 2
- Publication type:
- Article
Management of Oligoprogressive and Oligopersistent Disease in Advanced NSCLC.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, n. 1, p. 40
- By:
- Publication type:
- Article
Personalized Approaches to Breast Radiotherapy: Strategies for Treatment Refinement.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, n. 1, p. 30
- By:
- Publication type:
- Article
Chimeric Antigen Receptor T-Cell Therapy for T-Cell Acute Lymphocytic Leukemia.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, n. 1, p. 28
- By:
- Publication type:
- Article
Novel Approaches to Optimization of Drug Dosages.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, n. 1, p. 26
- By:
- Publication type:
- Article
Professor of Medicine, Surgery, Pharmacology, and Cancer Biology Director of Research Duke Cancer Institute Center for Prostate and Urologic Cancers Durham, North Carolina.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, n. 1, p. 21
- By:
- Publication type:
- Article
The Role of CTLA-4 Inhibition in Immunotherapy for MSI-H/dMMR Metastatic Colorectal Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, n. 1, p. 18
- By:
- Publication type:
- Article
New Cell Surface Targets in Prostate Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, n. 1, p. 10
- By:
- Publication type:
- Article
Lumpers and Splitters.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, n. 1, p. 8
- By:
- Publication type:
- Article